Related Experiment Video

Updated: May 12, 2026

Absorption of Nasal and Bronchial Fluids: Precision Sampling of the Human Respiratory Mucosa and Laboratory Processing of Samples
11:54

Absorption of Nasal and Bronchial Fluids: Precision Sampling of the Human Respiratory Mucosa and Laboratory Processing of Samples

Published on: January 21, 2018

Increased cys-leukotrienes in exhaled breath condensate and decrease of PNIF after intranasal allergen challenge

Wioletta Zagórska1, Katarzyna Grzela, Marek Kulus

  • 1Department of Pediatrics, Pneumonology and Allergology, Medical University of Warsaw, Warsaw, Poland.

Archivum Immunologiae Et Therapiae Experimentalis
|April 9, 2013
PubMed

Insights

Measuring cysteinyl leukotrienes (cysLT) in exhaled breath condensate (EBC) can help diagnose allergic rhinitis in children. Combining cysLT with nasal inspiratory flow measurements offers a highly sensitive and specific non-invasive diagnostic approach.

Area of Science:

  • Respiratory Medicine
  • Allergology
  • Biomarker Discovery

Background:

  • Exhaled breath condensate (EBC) contains inflammatory mediators, offering a non-invasive method for assessing respiratory diseases.
  • Concentrations of these mediators in EBC correlate with inflammatory response severity, aiding disease monitoring and treatment evaluation.
  • Allergic rhinitis diagnosis in children often relies on invasive methods; non-invasive biomarkers are needed.

Purpose of the Study:

  • To evaluate cysteinyl leukotrienes (cysLT) in EBC as non-invasive diagnostic markers for pediatric allergic rhinitis.
  • To assess the diagnostic performance of peak nasal inspiratory flow (PNIF) changes after allergen challenge.
  • To determine the combined diagnostic utility of EBC cysLT and PNIF changes.

Main Methods:

  • Measurement of cysLT concentrations in EBC from children.
  • Assessment of the change in peak nasal inspiratory flow (ΔPNIF) before and after intranasal allergen challenge.
  • Statistical analysis to determine sensitivity, specificity, and optimal thresholds for individual and combined markers.

Main Results:

  • EBC cysLT alone distinguished allergic rhinitis from healthy individuals with 87.8% sensitivity and 76.4% specificity (threshold 39.05 pg/ml).
  • ΔPNIF achieved 76.8% sensitivity and 78.6% specificity (threshold -3.2 l/min).
  • Combining EBC cysLT and ΔPNIF yielded 100% sensitivity and 84.6% specificity.

Conclusions:

  • EBC cysLT measurement is a promising non-invasive biomarker for pediatric allergic rhinitis.
  • The combination of EBC cysLT and ΔPNIF significantly enhances diagnostic accuracy.
  • Further studies are needed to confirm the clinical utility of this combined approach, especially in younger children.

More Related Videos

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels05:31

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels

Published on: August 7, 2017

Immunofluorescent Labeling in Nasal Mucosa Tissue Sections of Allergic Rhinitis Rats via Multicolor Immunoassay06:08

Immunofluorescent Labeling in Nasal Mucosa Tissue Sections of Allergic Rhinitis Rats via Multicolor Immunoassay

Published on: September 22, 2023

Related Concept Videos

Asthma I: Introduction01:28

Asthma I: Introduction

Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
Allergic Reactions02:06

Allergic Reactions

Overview
Asthma-I: Introduction01:29

Asthma-I: Introduction

Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Asthma III: Clinical Manifestations01:13

Asthma III: Clinical Manifestations

Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...